Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

5'-ASCSASTSCSASGSTSCSTSGSASUSASASGSCSTSA-3'

EU orphan designation number: EU/3/15/1451   
Active ingredient: 5'-ASCSASTSCSASGSTSCSTSGSASUSASASGSCSTSA-3'
Indication: Treatment of Alport syndrome
Sponsor: CTI Clinical Trial and Consulting Services Europe GmbH
Schillerstraße 1/15, 89077 Ulm, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
23/03/2015 Orphan designation EMA/OD/238/14 (2015)2017 of 19/03/2015